New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast
Andrew C Palfreeman, Kay E McNamee, Fiona E McCann The Kennedy Institute of Rheumatology, Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, London, UK Abstract: Psoriasis is a chronic inflammatory skin disease, most commonly resulting in the occurre...
Saved in:
Main Authors: | Palfreeman AC (Author), McNamee KE (Author), McCann FE (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2013-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Update on the treatment of psoriasis and psoriatic arthritis – role of apremilast
by: Forchhammer S, et al.
Published: (2015) -
[Translated article] Effectiveness and Drug Survival of Apremilast in 65 Patients With Psoriasis and/or Psoriatic Arthritis
by: P. Garbayo Salmons, et al.
Published: (2022) -
Acrodermatitis continua of Hallopeau with psoriatic arthritis treated with biologics and apremilast
by: Shohei Igari, et al.
Published: (2023) -
Psoriasis and Psoriatic Arthritis in ChildhoodPsoriasis and Psoriatic Arthritis in Childhood
by: Nikolay N. Murashkin, et al.
Published: (2020) -
Itolizumab - A New Biologic for Management of Psoriasis and Psoriatic Arthritis
by: Ganesh Pai, et al.
Published: (2017)